Menu
Search
|

Menu

Close
X

Seattle Genetics Inc SGEN.OQ (NASDAQ Stock Exchange Global Select Market)

54.48 USD
-0.37 (-0.67%)
As of Feb 16
chart
Previous Close 54.85
Open 54.80
Volume 405,159
3m Avg Volume 404,285
Today’s High 55.81
Today’s Low 54.29
52 Week High 71.31
52 Week Low 45.31
Shares Outstanding (mil) 143.03
Market Capitalization (mil) 8,225.50
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.27 Mean rating from 15 analysts

KEY STATS

Revenue (mm, USD)
FY17
482
FY16
418
FY15
337
EPS (USD)
FY17
-0.889
FY16
-0.994
FY15
-0.939
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
19.18
5.77
Price to Book (MRQ)
vs sector
14.26
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-29.99
14.43
Return on Equity (TTM)
vs sector
-32.73
16.13

EXECUTIVE LEADERSHIP

Clay Siegall
Chairman of the Board, President, Chief Executive Officer, Since 2004
Salary: $852,354.00
Bonus: $985,000.00
Todd Simpson
Chief Financial Officer, Since 2005
Salary: $475,371.00
Bonus: $269,500.00
Jean Liu
Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary, Since 2014
Salary: $399,829.00
Bonus: $217,681.00
Darren Cline
Executive Vice President - Commercial, Since 2016
Salary: --
Bonus: --
Jonathan Drachman
Chief Medical Officer, Executive Vice President - Research and Development, Since 2013
Salary: $510,167.00
Bonus: $294,600.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

21823 30th Dr SE
BOTHELL   WA   98021-3907

Phone: +1425.5274000

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company's pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.

SPONSORED STORIES